Sensible Biotherapeutics has been actively developing a prospective COVID-19 drug designed to potentially halt replication of the virus within human cells. The primary drug candidate in development is titled SBT-0704, while we are also exploring a potential drug candidate titled SBT-0803.

​

SBT-0803 and SBT-0704 are in early stages of development and Sensible Biotherapeutics is welcoming collaboration by third parties to propel these projects further. To request a PDF prospectus detailing the mechanism and potential efficacy of this drug in the fight against COVID-19, please email us at general@sensiblebiotherapeutics.com. 

​

In addition to SBT-0803, Sensible Biotherapeutics is actively developing a prophylactic drug designed to potentially prevent the SARS-CoV-2 virus from infecting the patient altogether. Compound SBT-0704 appears to show promise of being a possibly effective prophylactic treatment, but may also be useful in treating actively infected patients.
In addition to promising data already gathered on SBT-0704, a third treatment involving the use of a medical device is also in development, and is reserved only for patients with most serious forms of the illness with systemic viremia. It is designed to prevent what would otherwise be a fatal outcome, and may also substantially reduce the length of hospitalization and recovery time for COVID-19 patients with a less severe form of the illness.